1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Our Stock is Getting So Cheap, Benco or Burkhart Could Buy Us Now

Discussion in 'Patterson Dental Supply' started by anonymous, Aug 16, 2019 at 7:55 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The company is certainly a take-over target with the stock price this low. A 50% Premium to yesterday’s closing price, still puts in just under $25.
    Most stock holders would say “yes” to a price of $25 or thereabouts. A far cry from its height of $50.
     

  2. anonymous

    anonymous Guest

    This is what happens when you have poor leadership that broke a solid company, and then hired replacements (just a few, don't want to rock the boat too much) that either don't know what they are doing or aren't willing to burn down the rotting house and build it up again.
     
  3. anonymous

    anonymous Guest

    Burkhart isn't big enough to buy, they do only about $140-150mm/yearly sales, wouldn't know what to do with the crap stew in MN. Benco however has the muscle to do it but why? They're better off to let us fail and pick up the pieces when we go under.